Uganda has made history in the battle against HIV/AIDS by granting approval to lenacapavir, a groundbreaking twice-yearly injectable drug that delivers six full months of protection against the virus in a single dose.
Announced by the National Drug Authority as a true “game-changer,” this long-acting pre-exposure prophylaxis (PrEP) offers a powerful alternative to daily oral pills, especially for those who face stigma, inconsistent healthcare access, or difficulty maintaining strict regimens. With Uganda’s adult HIV prevalence standing at approximately 5.4%, the arrival of lenacapavir strengthens the country’s resolve to help meet the global goal of ending AIDS as a public health threat by 2030.
…CONTINUE READING
Leave a Reply